Shopping Cart
Remove All
Your shopping cart is currently empty
Cbl-b-IN-29
Catalog No. T213908 Copy Product Info
🥰Excellent
Cbl-b-IN-29 is an orally active inhibitor of CBL-B. It effectively binds to the active site of CBL-B, thereby inhibiting the function of the immune E3 ubiquitin ligase. Cbl-b-IN-29 can induce the release of IL-2 from Jurkat cells with an EC50 of 159 nM. This compound exhibits significant antitumor efficacy in vivo, showing good tolerance with no adverse effects observed. Cbl-b-IN-29 is applicable in cancer immunotherapy and related studies involving colon cancer and tumor immunotherapy combinations.
Cbl-b-IN-29
Copy Product Info🥰Excellent
Catalog No. T213908
Cbl-b-IN-29 is an orally active inhibitor of CBL-B. It effectively binds to the active site of CBL-B, thereby inhibiting the function of the immune E3 ubiquitin ligase. Cbl-b-IN-29 can induce the release of IL-2 from Jurkat cells with an EC50 of 159 nM. This compound exhibits significant antitumor efficacy in vivo, showing good tolerance with no adverse effects observed. Cbl-b-IN-29 is applicable in cancer immunotherapy and related studies involving colon cancer and tumor immunotherapy combinations.
Cbl-b-IN-29
Cas No. 3070411-10-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Cbl-b-IN-29 is an orally active inhibitor of CBL-B. It effectively binds to the active site of CBL-B, thereby inhibiting the function of the immune E3 ubiquitin ligase. Cbl-b-IN-29 can induce the release of IL-2 from Jurkat cells with an EC50 of 159 nM. This compound exhibits significant antitumor efficacy in vivo, showing good tolerance with no adverse effects observed. Cbl-b-IN-29 is applicable in cancer immunotherapy and related studies involving colon cancer and tumor immunotherapy combinations. |
| In vitro | Cbl-b-IN-29 (compound 20) presents a low risk of CYP inhibition/induction and hERG inhibition. |
| In vivo | Cbl-b-IN-29 (compound 20) administered at 30 mg/kg orally once daily for 15 days, demonstrated significant antitumor efficacy and good animal tolerance in the CT26 syngeneic mouse tumor model, both as a monotherapy and in combination with the anti-mouse PD-1 antibody, with no adverse effects observed. |
| Molecular Weight | 499.63 |
| Formula | C30H34FN5O |
| Cas No. | 3070411-10-5 |
| Smiles | CN1C([C@@]2(C[C@H](C)C2)C3=CC(=CC=C3)C4=CC=5C(NC4=O)=C([C@H](NC6CCCC6)C)C=CC5F)=NN=C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Cbl-b-IN-29 | purchase Cbl-b-IN-29 | Cbl-b-IN-29 cost | order Cbl-b-IN-29 | Cbl-b-IN-29 in vivo | Cbl-b-IN-29 in vitro | Cbl-b-IN-29 formula | Cbl-b-IN-29 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.